Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma

Neurosurgery

Volumn 60, Issue SUPPL. 1, 2013, Pages 57-63

  Wang, Xin ^a   Ramaswamy, Vijay ^a   Remke, Marc ^a   Mack, Stephen C ^a   Dubuc, Adrian M ^a   Northcott, Paul A ^a   Taylor, Michael D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CANCER GENETICS; CANCER SURGERY; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; MEDULLOBLASTOMA; METASTASIS; PRIORITY JOURNAL; RISK ASSESSMENT; DRUG DEVELOPMENT; GENOMICS; HIGH RISK PATIENT; HISTOLOGY; INTRATUMORAL DRUG ADMINISTRATION; PRIMARY TUMOR; STUDY DESIGN;

CEREBELLAR NEOPLASMS; HUMANS; MEDULLOBLASTOMA;

EID: 84885809750     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.neu.0000430318.01821.6f     Document Type: Conference Paper

References (94)

1. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: New biological advances. Lancet Neurol. 2007;6(12):1073-1085
2. Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in pediatric oncology. Nat Rev Clin Oncol. 2011;8(9):540-549
3. Rutkowski S, Von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: An international meta-Analysis. J Clin Oncol. 2010;28(33):4961-4968
4. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(suppl 5):v1-v49
5. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-Adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-Term results from a prospective, multicentre trial. Lancet Oncol. 2006;7 (10):813-820
6. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult longterm survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA. 2003;290(12):1583-1592
7. Spiegler BJ, Bouffet E, Greenberg ML, Rutka JT, Mabbott DJ. Change in neurocognitive functioning after treatment with cranial radiation in childhood. JAMA. 2004;22(4):706-713
8. Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2396-2404
9. Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: Therapy at a crossroads. Arch Neurol. 2008;65(11):1419-1424
10. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24(12):1924-1931
11. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3(8):e3088
12. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29(11):1424-1430
13. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408-1414
14. Remke M, Hielscher T, Korshunov A, et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol. 2011; 29(29):3852-3861
15. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol. 2012;123(4): 465-472
16. Northcott PA, Rutka JT, Taylor MD. Genomics of medulloblastoma: From Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus. 2010;28(1):E6
17. Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Rev Neurother. 2012;12(7):871-884
18. Dubuc AM, Northcott PA, Mack S, et al. The genetics of pediatric brain tumors. Curr Neurol Neurosci Rep. 2010;10(3):215-223
19. Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148(1-2):59-71
20. Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012;488(7409):43-48
21. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012; 488(7409):106-110
22. Jones DT, Jäger N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012;488(7409):100-105
23. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016):435-439
24. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488 (7409):49-56
25. Scheel C, Onder T, Karnoub A, Weinberg RA. Adaptation versus selection: The origins of metastatic behavior. Cancer Res. 2007;67(24):11476-11479; discussion 11479-11480
26. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22(6):984-993
27. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: Present concepts of stratification into risk groups. Pediatr Neurosurg. 2003;39(2):60-67
28. Northcott PA, Hielscher T, Dubuc A, et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 2011;122(2):231-240
29. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25): 4202-4208
30. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114 (2):97-109
31. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352(10):978-986
32. Grill J, Dufour C, Kalifa C. High-dose chemotherapy in children with newly-diagnosed medulloblastoma. Lancet Oncol. 2006;7(10):787-789
33. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: Clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121(3):381-396
34. Cogen PH, Daneshvar L, Metzger AK, et al. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. Am J Hum Genet. 1992;50(3):584-589
35. Bayani J, Zielenska M, Marrano P, et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg. 2000;93(3):437-448
36. Zhang B, Chambers KJ, Leprince D, Faller DV, Wang S. Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene. 2009;28(5):651-661
37. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98(24):13790-13795
38. Gatza ML, Lucas JE, Barry WT, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010;107(15): 6994-6999
39. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110
40. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522
41. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011;20(2):143-157
42. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415(6870):436-442
43. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: An international meta-Analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473-484
44. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: The end of the beginning. Nat Rev Cancer. 2012;12(12):818-834
45. Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011;29(19): 2717-2723
46. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010;468(7327):1095-1099
47. Dubuc AM, Morrissy AS, Kloosterhof NK, et al. Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathol. 2012;123 (4):485-499
48. Ramaswamy V, Northcott PA, Taylor MD. FISH and chips: The recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet. 2011;204(11):577-588
49. Wang X, Venugopal C, Manoranjan B, et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene. 2011;31(2):187-199
50. Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular subgroup of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006;5(22):2666-2670
51. Lindsey JC, Hill RM, Megahed H, et al. TP53 mutations in favorable-risk Wnt/wingless-subtype medulloblastomas. J Clin Oncol. 2011;29(12): E344-e346
52. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31(3):306-310
53. Slade I, Murray A, Hanks S, et al. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer. 2011;10(2):337-342
54. Northcott PA, Shih DJ, Remke M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012;123(4):615-626
55. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. Cancer Cell. 2008;14(2):135-145
56. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12): 1173-1178
57. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326(5952):572-574
58. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010; 11(10):685-696
59. Dubuc AM, Northcott PA, Kenney AM, Taylor MD. Calculating a cure for cancer: Managing medulloblastoma MATH1-ematically. Expert Rev Neurother. 2010;10(10):1489-1492
60. Bertrand KC, Mack SC, Northcott PA, et al. PCDH10 is a candidate tumour suppressor gene in medulloblastoma. Childs Nerv Syst. 2011; 27(8):1243-1249
61. Alimova I, Venkataraman S, Harris P, et al. Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer. 2012;131(8):1800-1809
62. Pei Y, Brun SN, Markant SL, et al. WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development. 2012;139(10):1724-1733
63. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71(2):435-444
64. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51ra70
65. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004;64(21): 7794-7800
66. Grammel D, Warmuth-Metz M, Von Bueren AO, et al. Sonic hedgehogassociated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathol. 2012;123(4):601-614
67. Oliver TG, Read TA, Kessler JD, et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development. 2005;132(10):2425-2439
68. Schüller U, Heine VM, Mao J, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 2008;14(2):123-134
69. Northcott PA, Fernandez-LA, Hagan JP, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-Treated cerebellar neural precursors. Cancer Res. 2009;69(8):3249-3255
70. Pei Y, Moore CE, Wang J, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012;21(2):155-167
71. Swartling FJ, Savov V, Persson AI, et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 2012;21(5):601-613
72. Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35
73. Korshunov A, Remke M, Kool M, et al. Biological and clinical heterogeneity of MYCN-Amplified medulloblastoma. Acta Neuropathol. 2012; 123(4):515-527
74. Unterberger A, Dubuc AM, Taylor MD. Genome-wide methylation analysis. Cancer Epigenetics. Dumitrescu RG, Verma M, eds. New York, NY: Humana Press. Volume 863; 2012, pp 303-317. ISBN: 978-1-61779-612-8
75. Baylin SB, Jones PA. A decade of exploring the cancer epigenome: Biological and translational implications. Nat Rev Cancer. 2011;11(10): 726-734
76. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet. 2009;41(4):465-472
77. Dubuc AM, Remke M, Korshunov A, et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol. 2012;125(3):373-384
78. Eyal A, Engelender S. Synphilin isoforms and the search for a cellular model of Lewy body formation in Parkinson's disease. Cell Cycle. 2006; 5(18):2082-2086
79. Wu X, Northcott PA, Croul S, Taylor MD. Mouse models of medulloblastoma. Chin J Cancer. 2011;30(7):442-449
80. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70
81. Kongkham PN, Northcott PA, Ra YS, et al. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res. 2008;68(23):9945-9953
82. Nakahara Y, Northcott PA, Li M, et al. Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia. 2010;12(1): 20-27
83. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6): 810-817
84. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532-536
85. Diaz LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537-540
86. Szerlip NJ, Pedraza A, Chakravarty D, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A. 2012;109(8):3041-3046
87. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 2005;436(7048):221-226
88. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005;436(7048):272-276
89. Mann KM, Ward JM, Yew CC, et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2012;109(16):5934-5941
90. Wu X, Northcott PA, Dubuc A, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature. 2012;482(7386): 529-533
91. Mumert M, Dubuc A, Wu X, et al. Functional genomics identifies drivers of medulloblastoma dissemination. Cancer Res. 2012;72(19):4944-4953
92. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337
93. Cancer Genome Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-1068
94. Sengupta R, Dubuc A, Ward S, et al. CXCR4 activation defines a new subgroup of sonic hedgehog-driven medulloblastoma. Cancer Res. 2012; 72(1):122-132